{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:03:16Z","timestamp":1789426996585,"version":"build-2803163510"},"reference-count":74,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.jaip.2017.03.015","type":"journal-article","created":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T05:30:42Z","timestamp":1493962242000},"page":"593-599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Immediate Hypersensitivity Reaction to Chemotherapeutic Agents"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1034-7580","authenticated-orcid":false,"given":"Pedro","family":"Giavina-Bianchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarita U.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleena","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2017.03.015_bib1","unstructured":"World Health Organization. Available from: http:\/\/www.who.int. Accessed April 5, 2017."},{"key":"10.1016\/j.jaip.2017.03.015_bib2","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jaci.2014.08.018","article-title":"Fatal anaphylaxis in the United States, 1999-2010: temporal patterns and demographic associations","volume":"134","author":"Jerschow","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.03.015_bib3","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jaci.2003.12.591","article-title":"Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003","volume":"113","author":"Johansson","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.03.015_bib4","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1056\/NEJM196611172752009","article-title":"Immunologic mechanisms of penicillin allergy: a haptenic model system for the study of allergic diseases of man","volume":"275","author":"Levine","year":"1966","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2017.03.015_bib5","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1398-9995.1995.tb01200.x","article-title":"Nonimmediate reactions to betalactams: prevalence and role of the different penicillins","volume":"50","author":"Terrados","year":"1995","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2017.03.015_bib6","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1398-9995.2004.00678.x","article-title":"Diagnosis of nonimmediate reactions to beta-lactam antibiotics","volume":"59","author":"Romano","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2017.03.015_bib7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jaci.2011.08.042","article-title":"Drug hypersensitivity reactions: inconsistency in the use of the classification of immediate and nonimmediate reactions","volume":"129","author":"Bircher","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.03.015_bib8","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/all.12350","article-title":"International Consensus on drug allergy","volume":"69","author":"Demoly","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2017.03.015_bib9","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1182\/blood-2012-07-442541","article-title":"The high-affinity human IgG receptor FcgammaRI (CD64) promotes IgG-mediated inflammation, anaphylaxis, and antitumor immunotherapy","volume":"121","author":"Mancardi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2017.03.015_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.06.058","article-title":"Mechanisms of anaphylaxis in human low-affinity IgG receptor locus knock-in mice","volume":"139","author":"Gillis","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.03.015_bib11","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.iac.2014.04.003","article-title":"Adverse events to nontargeted and targeted chemotherapeutic agents: emphasis on hypersensitivity responses","volume":"34","author":"Baldo","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2017.03.015_bib12","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.iac.2004.03.012","article-title":"Immune mechanism of drug hypersensitivity","volume":"24","author":"Pichler","year":"2004","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2017.03.015_bib13","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jaip.2016.08.012","article-title":"Carboplatin-allergic patients undergoing desensitization: prevalence and impact of the BRCA 1\/2 mutation","volume":"5","author":"Galvao","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2017.03.015_bib14","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1001\/jama.1992.03490240060037","article-title":"Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome)","volume":"268","author":"Bone","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2017.03.015_bib15","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2017.03.015_bib16","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/PEC.0000000000000195","article-title":"Tumor lysis syndrome: risk factors, diagnosis, and management","volume":"30","author":"Burns","year":"2014","journal-title":"Pediatr Emerg Care"},{"key":"10.1016\/j.jaip.2017.03.015_bib17","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1634\/theoncologist.2014-0358","article-title":"Advances in anticancer immunotoxin therapy","volume":"20","author":"Alewine","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.jaip.2017.03.015_bib18","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.anai.2015.07.017","article-title":"Risk-stratification protocol for carboplatin and oxaliplatin hypersensitivity: repeat skin testing to identify drug allergy","volume":"115","author":"Wang","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2017.03.015_bib19","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s40521-015-0060-2","article-title":"Rapid desensitization in immediate hypersensitivity reaction to drugs","volume":"2","author":"Giavina-Bianchi","year":"2015","journal-title":"Curr Treatment Options Allergy"},{"key":"10.1016\/j.jaip.2017.03.015_bib20","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jaip.2015.12.019","article-title":"Safety, costs, and efficacy of rapid drug desensitizations to chemotherapy and monoclonal antibodies","volume":"4","author":"Sloane","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2017.03.015_bib21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0305-7372(03)00116-6","article-title":"Classification of anticancer drugs\u2013a new system based on therapeutic targets","volume":"29","author":"Espinosa","year":"2003","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jaip.2017.03.015_bib22","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2014.59.9746","article-title":"Clinical cancer advances 2015: annual report on progress against cancer from the American Society of Clinical Oncology","volume":"33","author":"Masters","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaip.2017.03.015_bib23","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10555-013-9447-3","article-title":"Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch","volume":"32","author":"Baldo","year":"2013","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.jaip.2017.03.015_bib24","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jaci.2011.10.010","article-title":"A\u00a0protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions","volume":"129","author":"Patil","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.03.015_bib25","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.jaci.2015.10.039","article-title":"Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions","volume":"137","author":"Picard","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.03.015_bib26","first-page":"728","article-title":"Basophil activation test is a relevant biomarker of the outcome of rapid desensitization in platinum compounds-allergy","volume":"5","author":"Giavina-Bianchi","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.03.015_bib27","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaip.2013.06.002","article-title":"Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy","volume":"1","author":"Caiado","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2017.03.015_bib28","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1248\/bpb.b12-00150","article-title":"Evaluation of basophil CD203c as a predictor of carboplatin-related hypersensitivity reaction in patients with gynecologic cancer","volume":"35","author":"Iwamoto","year":"2012","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.jaip.2017.03.015_bib29","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1111\/cas.12538","article-title":"Carboplatin-induced severe hypersensitivity reaction: role of IgE-dependent basophil activation and FcepsilonRI","volume":"105","author":"Iwamoto","year":"2014","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jaip.2017.03.015_bib30","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00105-008-1653-5","article-title":"Basophil activation test as in\u00a0vitro assay for cisplatin allergy [in German]","volume":"59","author":"Viardot-Helmer","year":"2008","journal-title":"Hautarzt"},{"key":"10.1016\/j.jaip.2017.03.015_bib31","first-page":"170","article-title":"Immunoglobulin E-mediated severe anaphylaxis to paclitaxel","volume":"20","author":"Prieto Garcia","year":"2010","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2017.03.015_bib32","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jaci.2009.02.042","article-title":"Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management","volume":"123","author":"Hesterberg","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.03.015_bib33","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/all.12105","article-title":"Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment","volume":"68","author":"Madrigal-Burgaleta","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2017.03.015_bib34","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/jjco\/hys006","article-title":"An experimental biological test to diagnose hypersensitivity reactions to carboplatin: new horizons for an old problem","volume":"42","author":"Pagani","year":"2012","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jaip.2017.03.015_bib35","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jaci.2013.06.038","article-title":"Basophil activation testing","volume":"132","author":"MacGlashan","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.03.015_bib36","doi-asserted-by":"crossref","first-page":"266","DOI":"10.5415\/apallergy.2013.3.4.266","article-title":"Recent applications of basophil activation tests in the diagnosis of drug hypersensitivity","volume":"3","author":"Song","year":"2013","journal-title":"Asia Pacific Allergy"},{"key":"10.1016\/j.jaip.2017.03.015_bib37","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1046\/j.1365-2222.2002.01305.x","article-title":"Flow cytometric basophil activation test by detection of CD63 expression in patients with immediate-type reactions to betalactam antibiotics","volume":"32","author":"Sanz","year":"2002","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2017.03.015_bib38","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2500\/aap.2011.32.3450","article-title":"Outcomes and safety of drug provocation tests","volume":"32","author":"Aun","year":"2011","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2017.03.015_bib39","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/all.12142","article-title":"Skin test concentrations for systemically administered drugs \u2013 an ENDA\/EAACI Drug Allergy Interest Group position paper","volume":"68","author":"Brockow","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2017.03.015_bib40","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1398-9995.2009.02228.x","article-title":"Determining the negative predictive value of provocation tests with beta-lactams","volume":"65","author":"Demoly","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2017.03.015_bib41","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jaip.2014.04.010","article-title":"Management of hypersensitivity reactions to carboplatin and paclitaxel in an outpatient oncology infusion center: a 5-year review","volume":"2","author":"Banerji","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2017.03.015_bib42","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ygyno.2004.11.043","article-title":"Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments","volume":"96","author":"Feldweg","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jaip.2017.03.015_bib43","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaci.2008.02.044","article-title":"Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases","volume":"122","author":"Castells","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.03.015_bib44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1081-1206(10)60247-5","article-title":"Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization","volume":"102","author":"Breslow","year":"2009","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2017.03.015_bib45","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1398-9995.2010.02441.x","article-title":"General considerations on rapid desensitization for drug hypersensitivity\u2014a consensus statement","volume":"65","author":"Cernadas","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2017.03.015_bib46","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.jaci.2009.09.009","article-title":"Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment","volume":"124","author":"Brennan","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.03.015_bib47","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/eji.201040810","article-title":"Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting FcepsilonRI internalization","volume":"41","author":"Sancho-Serra Mdel","year":"2011","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaip.2017.03.015_bib48","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.iac.2015.01.011","article-title":"Anaphylaxis to chemotherapy and monoclonal antibodies","volume":"35","author":"Castells","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2017.03.015_bib49","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40259-013-0066-x","article-title":"Drug desensitization in the management of hypersensitivity reactions to monoclonal antibodies and chemotherapy","volume":"28","author":"Mezzano","year":"2014","journal-title":"BioDrugs"},{"key":"10.1016\/j.jaip.2017.03.015_bib50","doi-asserted-by":"crossref","first-page":"AB59","DOI":"10.1016\/j.jaci.2013.12.235","article-title":"LAMP1 and CD63 expression in mouse mast cells and human basophils rendered hyporesponsive by antigen\/IgE-mediated activation and desensitization","volume":"133","author":"Giavina-Bianchi","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.03.015_bib51","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1111\/all.12228","article-title":"Rapid desensitization to chemotherapy and monoclonal antibodies is effective and safe","volume":"68","author":"Giavina-Bianchi","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2017.03.015_bib52","first-page":"72","article-title":"Rapid drug desensitization for hypersensitivity reactions to chemotherapy and monoclonal antibodies in the 21st century","volume":"24","author":"Castells Guitart","year":"2014","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2017.03.015_bib53","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ygyno.2014.01.042","article-title":"A\u00a0systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer","volume":"133","author":"Lorusso","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jaip.2017.03.015_bib54","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/j.ejca.2005.06.021","article-title":"Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients","volume":"41","author":"Maindrault-Goebel","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaip.2017.03.015_bib55","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/IGC.0b013e3181a1bf2e","article-title":"Incidence of carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies","volume":"19","author":"Koshiba","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.jaip.2017.03.015_bib56","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/(SICI)1096-911X(199903)32:3<183::AID-MPO4>3.0.CO;2-P","article-title":"Hypersensitivity to carboplatin in children","volume":"32","author":"Schiavetti","year":"1999","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.jaip.2017.03.015_bib57","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000055363","article-title":"Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience","volume":"61","author":"Polyzos","year":"2001","journal-title":"Oncology"},{"key":"10.1016\/j.jaip.2017.03.015_bib58","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1200\/JCO.1999.17.4.1141","article-title":"Clinical features of hypersensitivity reactions to carboplatin","volume":"17","author":"Markman","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaip.2017.03.015_bib59","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/207084","article-title":"Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review","volume":"2010","author":"Makrilia","year":"2010","journal-title":"Met Based Drugs"},{"key":"10.1016\/j.jaip.2017.03.015_bib60","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1136\/ijgc-00009577-200807000-00003","article-title":"Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer","volume":"18","author":"Gadducci","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.jaip.2017.03.015_bib61","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/bjc.2013.389","article-title":"Deleterious BRCA1\/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions","volume":"109","author":"Moon","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jaip.2017.03.015_bib62","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaip.2013.08.011","article-title":"Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization","volume":"2","author":"Wong","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2017.03.015_bib63","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jaci.2006.11.640","article-title":"Diagnostic and predictive value of skin testing in platinum salt hypersensitivity","volume":"119","author":"Leguy-Seguin","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.03.015_bib64","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1006\/gyno.2001.6331","article-title":"Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies","volume":"82","author":"Robinson","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jaip.2017.03.015_bib65","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/cncr.11379","article-title":"Hypersensitivity and idiosyncratic reactions to oxaliplatin","volume":"97","author":"Thomas","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jaip.2017.03.015_bib66","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jaip.2015.07.003","article-title":"Skin testing in the evaluation and management of carboplatin-related hypersensitivity reactions","volume":"3","author":"Lax","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2017.03.015_bib67","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaip.2017.03.015_bib68","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/IGC.0b013e3181a38e2f","article-title":"Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel","volume":"19","author":"Fader","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.jaip.2017.03.015_bib69","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ejps.2011.09.016","article-title":"Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20","volume":"45","author":"Weiszhar","year":"2012","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.jaip.2017.03.015_bib70","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2000.18.1.102","article-title":"Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center","volume":"18","author":"Markman","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaip.2017.03.015_bib71","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1006\/gyno.2001.6546","article-title":"A\u00a0comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel","volume":"84","author":"Kwon","year":"2002","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jaip.2017.03.015_bib72","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/archderm.136.12.1475","article-title":"Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin","volume":"136","author":"Lotem","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2017.03.015_bib73","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ygyno.2005.06.028","article-title":"Rapid inpatient\/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses","volume":"99","author":"Lee","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jaip.2017.03.015_bib74","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1080\/1120009X.1989.11738916","article-title":"Skin and perivascular toxicity induced experimentally by doxorubicin","volume":"1","author":"Balsari","year":"1989","journal-title":"J\u00a0Chemother (Florence, Italy)"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219817301861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219817301861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:12:49Z","timestamp":1761973969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219817301861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S2213219817301861"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2017.03.015","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immediate Hypersensitivity Reaction to Chemotherapeutic Agents","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2017.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}